Enanta Pharmaceuticals Announces Data Presentation at ESCMID Global 2024
Enanta Pharmaceuticals Announces Data Presentation at ESCMID Global 2024
WATERTOWN, Mass.--(BUSINESS WIRE)--Apr. 17, 2024-- Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for indications in virology and immunology, today announced that data from the company's SPRINT (SARS-Cov-2 PRotease INhibitor Treatment) study of EDP-235 has been accepted for a poster presentation at ESCMID Global 2024 (formerly ECCMID) being held April 27–30 in Barcelona, Spain.
馬薩諸塞州沃特敦--(美國商業資訊)--2024年4月17日-- Enanta 製藥有限公司 納斯達克股票代碼：ENTA）是一家致力於爲病毒學和免疫學適應症開發小分子藥物的臨床階段生物技術公司，今天宣佈了來自該公司SPRINT的數據（SARS-CoV-2 公關oease 在抑制者 T治療）EDP-235 研究已獲准在 4 月 27 日至 30 日在西班牙巴塞羅那舉行的 ESCMID Global 2024（前身爲 ECCMID）的海報展示。
The poster presentation includes primary and post-hoc analyses from the double-blind, placebo-controlled Phase 2 clinical trial of EDP-235, a 3CL protease inhibitor, in non-hospitalized, symptomatic adults with mild or moderate COVID-19 who were not at high risk for severe disease.
海報展示包括對於 EDP-235（一種3CL 蛋白酶抑制劑）的雙盲、安慰劑對照的 2 期臨床試驗的初步和事後分析，該試驗針對的是未住院、有症狀且患有輕度或中度 COVID-19 且患有嚴重疾病風險的成年人。
Poster Title: "Efficacy and Safety of EDP-235 in Non-Hospitalized Adults with Mild or Moderate COVID-19: Results from the Phase 2 SPRINT Study"
Abstract Number: 02980
Poster Number: PO423
Day: April 27, 2024
Time: 12:00 p.m. CEST / 6:00 a.m. ET
Session Location: Poster Area
Session Title: COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)
Presenter: Scott T. Rottinghaus, M.D., Chief Medical Officer, Enanta Pharmaceuticals, Inc.
海報標題: “EDP-235 對未住院成人的輕度或中度 COVID-19 的療效和安全性：2 期 SPRINT 研究的結果” 摘要編號： 02980
海報編號:PO423
天: 2024 年 4 月 27 日
時間:中歐標準時間下午 12:00 /美國東部時間上午 6:00
會話地點: 海報區
會話標題: COVID-19（包括病毒學、流行病學、進化、免疫反應、診斷、治療、疫苗接種、預防、反應和社會影響）
演示者: Scott T. Rottinghaus，醫學博士，Enanta Pharmicals, Inc. 首席醫學官
The scientific program for ESCMID Global 2024 can be found at https://www.eccmid.org/scientific-programme
ESCMID Global 2024 的科學計劃可在以下網址找到 https://www.eccmid.org/scientific-programme
About Enanta Pharmaceuticals, Inc.
Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs with an emphasis on indications in virology and immunology. Enanta's research and development programs are currently focused on respiratory syncytial virus (RSV) and chronic spontaneous urticaria (CSU) and the company has previously advanced clinical-stage compounds for SARS-CoV-2 (COVID-19) and chronic hepatitis B virus (HBV) infection.
關於 Enanta 製藥有限公司
Enanta正在利用其強大的化學驅動方法和藥物發現能力，成爲以病毒學和免疫學適應症爲重點的小分子藥物發現和開發領域的領導者。Enanta的研發項目目前側重於呼吸道合胞病毒（RSV）和慢性自發性蕁麻疹（CSU），該公司此前已經開發了用於SARS-CoV-2（COVID-19）和慢性乙型肝炎病毒（HBV）感染的臨床階段化合物。
Glecaprevir, a protease inhibitor discovered by Enanta, is part of one of the leading treatment regimens for curing chronic hepatitis C virus infection (HCV) and is sold by AbbVie in numerous countries under the trade names MAVYRET(U.S.) and MAVIRET(ex-U.S.) (glecaprevir/pibrentasvir). A portion of Enanta's royalties from hepatitis C virus (HCV) products developed under its collaboration with AbbVie contribute ongoing funding to Enanta's operations. Please visit http://www.enanta.com for more information.
Glecaprevir是Enanta發現的一種蛋白酶抑制劑，是治療慢性丙型肝炎病毒感染（HCV）的主要治療方案之一，由艾伯維在多個國家以商品名MAVYRET出售（美國）和 MAVIRET（前美國）（格列卡普雷韋/匹布倫他韋）。Enanta與艾伯維合作開發的丙型肝炎病毒（HCV）產品的部分特許權使用費爲Enanta的運營提供了持續的資金。請訪問 http://www.enanta.com 了解更多信息。
View source version on businesswire.com: https://www.businesswire.com/news/home/20240417219973/en/
Media and Investors Contact
Jennifer Viera
jviera@enanta.com
媒體和投資者聯繫方式
詹妮弗·維埃拉
jviera@enanta.com
Source: Enanta Pharmaceuticals, Inc.
來源：Enanta Pharmicals, Inc
譯文內容由第三人軟體翻譯。